Biopharmaceutical News and Research

RSS

Experimental cancer drug MI-219 promising in preclinical studies

Researchers have long searched for a novel cancer drug that activates a certain protein to kill tumor cells.

4 Mar 2008

FDA approves Aloxi injection for prevention of postoperative nausea and vomiting

Eisai Corporation of North America, its U.S. subsidiary, MGI PHARMA, INC., and Helsinn Healthcare SA today announced that the U.S. Food and Drug Administration (FDA) has approved Aloxi (palonosetron hydrochloride) injection for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

4 Mar 2008

Nasal vaccine for smallpox protects animals against 77 times the potentially lethal dose of smallpox

Scientists at NanoBio Corporation and the University of Michigan have demonstrated their nasally delivered vaccinia vaccine can protect animals against 77 times the potentially lethal dose of smallpox, and without the safety risks of current vaccines for smallpox.

27 Feb 2008

PolyTherics and Celtic Pharma sign agreement to explore technologies for improved drug performance

PolyTherics Limited, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, and Celtic Pharma Development Services Bermuda Ltd, a subsidiary of Celtic Pharmaceutical Holdings LP, a global private equity investment fund focused on the biopharma industry, today announced that they have entered into a broad research collaboration agreement.

26 Feb 2008

Experimental drug shows promise for cystic fibrosis

An experimental drug that has proven effective in treating muscular dystrophy also works for cystic fibrosis, according to researchers at the University of Alabama at Birmingham (UAB).

5 Feb 2008

FDA approves only once-daily inhaled corticosteroid for children

Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved ASMANEX TWISTHALER 110 mcg (mometasone furoate inhalation powder) for the maintenance treatment of asthma as a preventive therapy in patients 4 to 11 years of age.

4 Feb 2008

Advances in age-related macular degeneration treatment

A new study of age-related macular degeneration (AMD), a disease that affects more than nine million Americans, will pave the way for the biopharmaceutical industry to develop better treatments and cures, according to the Foundation Fighting Blindness, which partially funded the research.

4 Feb 2008

Stem cell therapy studies for stroke, cerebral palsy prepare for clinical trials

Finding answers about optimal dosage and timing for stem cell therapy in adults with strokes and newborns with ischemic injuries is a goal of two new federally funded studies.

31 Jan 2008

M. D. Anderson, AstraZeneca form alliance to advance understanding of cancer-related pain

The University of Texas M. D. Anderson Cancer Center and AstraZeneca (NYSE:AZN) today announced that they will collaborate to help advance understanding of neuropathic pain caused by cancer chemotherapy, a side effect that often limits optimal therapeutic dosing in cancer treatments.

25 Jan 2008

FDA extends review of Genasense NDA appeal in chronic lymphocytic leukemia

Genta Incorporated has announced that the Food and Drug Administration (FDA) has extended its review of Genta's appeal of the non- approvable decision for a New Drug Application (NDA) that proposed the use of Genasense (oblimersen sodium injection) plus chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.

15 Jan 2008

Morphotek announces agreement for development of antibodies to treat prostate cancer

Morphotek, Inc., a subsidiary of Eisai Co., Ltd., has announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of therapeutic antibodies to a cancer-associated protein identified by NCI researchers.

10 Jan 2008

A look at China's most innovative health biotechnology companies

Government funds innovation but venture capital needed; Wary investors 'need to be shown the exits'; Returning 'sea turtles' bring expertise, international credibility

8 Jan 2008

FDA concludes no increased risk of cardiac events for patients treated with omeprazole and Nexium

The US Food and Drug Administration (FDA) has issued its final assessment of two small, open, long-term, clinical studies in patients with gastro-esophageal reflux disease (GERD), comparing anti-reflux surgery with either omeprazole (SOPRAN study) or NEXIUM (LOTUS study) treatment.

10 Dec 2007

Innovative drug production project secures funding from Technology Strategy Board

PolyTherics, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, has announced that it has secured funding from the Technology Strategy Board.

29 Nov 2007

Isotechnika granted Norwegian patent for lead immunosuppressive drug

Isotechnika Inc. has announced that the Company has been issued Norwegian Patent No. 324042 for its lead immunosuppressive drug, ISA247.

27 Nov 2007

New non-addictive pain-killers

Two University of Adelaide pharmacologists working with one the world's leading neuroscientists have helped pave the way for the development of new pain-killing drugs that are not addictive.

20 Nov 2007

Pfizer to acquire Coley Pharmaceutical Group

Pfizer has announced that it has entered into an agreement to acquire Coley Pharmaceutical Group, a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases.

19 Nov 2007

Bavarian Nordic updates on vaccine project pipeline

In a business update, Danish-based biopharmaceutical company Bavarian Nordic, reported a number of developments in its vaccine project pipeline.

6 Nov 2007

Combination targets offer new hope in fight against cancer

While some targeted therapies - drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells - work well by themselves, increasingly researchers are finding that they work better when teamed with other targeted and conventional therapies.

24 Oct 2007

Orexigen presents findings on obesity drug candidates

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, has presented the results of a preclinical study that further supports the Company's understanding of an aspect of the mechanism of action of Contrave, one of its two late-stage obesity drug candidates.